Intellia Therapeutics Inc. (NTLA) stock
Price, quality score, analyst targets, a 30-day Kronos AI forecast and a Shariah screen for Intellia Therapeutics Inc., updated every trading day.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances
Intellia Therapeutics Inc. (NTLA) is a Health Care company in Biotechnology: In Vitro & In Vivo Diagnostic Substances, worth $1.7B. It trades at $13.32, up 8.47% today. 13 analysts' average target of $19.91 implies +49.5% from today's price. Kronos AI's 30-day forecast is −6.0% (1 of 8 simulated paths end higher).
Open the full interactive analysis →Charts, technical signals, DCF fair value and ownership
Analyst price targets
| Average target | $19.91 |
| Low – high | $8.00 – $49.00 |
| Analysts | 13 |
| Upside to average | +49.5% |
Kronos AI 30-day forecast
| Expected close | $11.54 (−6.0%) |
| Likely range | −7.5% … +0.4% |
| As of | 2026-10-27 |
Quality scores
Not scored: the financial data for this listing is incomplete.
Shariah screen
| Business activity | Passes |
| Debt and cash (AAOIFI 30%) | Not checked for this listing |
Halal Health Care stocks · Zakat calculator · Purification calculator